Sotera Health (NASDAQ:SHC) Price Target Raised to $18.00 at JPMorgan Chase & Co.

Sotera Health (NASDAQ:SHC) had its target price hoisted by JPMorgan Chase & Co. from $16.00 to $18.00 in a report issued on Friday morning,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the stock.

Other research analysts also recently issued reports about the stock. The Goldman Sachs Group started coverage on shares of Sotera Health in a report on Friday, June 5th. They issued a “buy” rating and a $20.00 price target for the company. Piper Sandler reiterated an “overweight” rating and issued a $22.00 price objective (down from $24.00) on shares of Sotera Health in a research report on Wednesday, May 6th. Weiss Ratings raised Sotera Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, July 9th. Citigroup lifted their target price on shares of Sotera Health from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Friday. Finally, UBS Group set a $19.00 price objective on Sotera Health in a research report on Wednesday, June 24th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $21.50.

Sotera Health Stock Performance

Shares of SHC opened at $18.86 on Friday. The stock’s 50-day simple moving average is $17.13 and its 200 day simple moving average is $16.33. The stock has a market capitalization of $5.38 billion, a price-to-earnings ratio of 33.09 and a beta of 1.77. The company has a debt-to-equity ratio of 3.19, a quick ratio of 2.54 and a current ratio of 2.80. Sotera Health has a 52-week low of $12.94 and a 52-week high of $19.85.

Sotera Health (NASDAQ:SHC) last posted its earnings results on Thursday, August 6th. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.02. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%.The business had revenue of $321.38 million during the quarter, compared to analyst estimates of $309.70 million. During the same quarter in the previous year, the firm earned $0.20 EPS. The company’s quarterly revenue was up 9.2% compared to the same quarter last year. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. Research analysts forecast that Sotera Health will post 0.87 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of Sotera Health stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $15.17, for a total transaction of $193,194,516.17. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 15.36% of the stock is owned by insiders.

Hedge Funds Weigh In On Sotera Health

A number of institutional investors have recently added to or reduced their stakes in the company. Empowered Funds LLC boosted its holdings in shares of Sotera Health by 11.1% during the 1st quarter. Empowered Funds LLC now owns 28,512 shares of the company’s stock valued at $332,000 after buying an additional 2,845 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Sotera Health by 14.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company’s stock worth $3,999,000 after acquiring an additional 43,471 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Sotera Health by 125.5% in the 1st quarter. Acadian Asset Management LLC now owns 25,192 shares of the company’s stock worth $293,000 after acquiring an additional 14,018 shares in the last quarter. Creative Planning lifted its position in Sotera Health by 15.3% during the 2nd quarter. Creative Planning now owns 20,186 shares of the company’s stock valued at $224,000 after acquiring an additional 2,673 shares during the period. Finally, Invesco Ltd. lifted its position in Sotera Health by 4.2% during the 2nd quarter. Invesco Ltd. now owns 319,156 shares of the company’s stock valued at $3,549,000 after acquiring an additional 12,758 shares during the period. Institutional investors own 91.03% of the company’s stock.

Key Stories Impacting Sotera Health

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Strong Q2 results and raised outlook: Sotera Health reported adjusted EPS of $0.26, above the $0.24 consensus, while revenue increased 9.2% year over year to $321.4 million, exceeding estimates of $309.7 million. Adjusted EBITDA rose 10%, and net income increased to $53.6 million from $8.0 million a year earlier. Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
• Positive Sentiment: Management raised full-year 2026 guidance: The company increased its constant-currency revenue growth outlook to 5.25%-6.75%, adjusted EBITDA growth outlook to 5.75%-7.25%, and adjusted EPS guidance to $0.95-$1.01. It also expects lower interest expense following a term-loan repricing that should save approximately $3.5 million annually. Sotera Health Company Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Piper Sandler became more bullish: The firm reaffirmed its “overweight” rating and raised its price target from $22 to $25, implying substantial upside from the recent trading level. Benzinga analyst update
• Neutral Sentiment: JPMorgan’s target increase was less constructive: JPMorgan lifted its target from $16 to $18 but maintained a “neutral” rating, leaving its target below the current share price. This may be limiting enthusiasm following the earnings-driven rally. Benzinga analyst update
• Negative Sentiment: Leverage and ongoing risks remain: SHC still carries approximately $2.2 billion of debt, while litigation related to ethylene oxide facilities, inflationary costs and regulatory risks remain potential overhangs. The stock’s valuation also appears demanding relative to JPMorgan’s neutral view.

Sotera Health Company Profile

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.